イロックス・ファーマシューティカルズ
ELOX
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.88 | $0 | -$5M |
| 2025 Q1 | -4.95 | $0 | $1M |
| 2023 Q3 | -14.41 | $0 | -$3M |
| 2023 Q2 | -21.56 | $0 | -$2M |
| 2023 Q1 | -31.68 | $0 | -$7M |
| 2022 Q4 | -32.12 | $0 | — |
| 2022 Q3 | -38.17 | $0 | -$7M |
| 2022 Q2 | -53.90 | $0 | -$10M |